BRÈVE

sur Kuros Biosciences AG (isin : CH0325814116)

Kuros Biosciences Reports Significant Sales Growth and Exceeds Cash Flow Breakeven

Kuros Biosciences AG has announced a notable 149% rise in direct MagnetOs sales, reaching CHF 50.6 million in the first nine months of 2024. This is a significant increase compared to CHF 20.4 million during the same period in 2023. The total sales for the Kuros Medical Devices segment reached CHF 51.1 million, up from CHF 21.3 million the previous year.

The company's Medical Devices segment reported an EBITDA of CHF 13.3 million, with an EBITDA margin of 26%, reflecting profitable operations. Kuros also reported cash and cash equivalents of CHF 15.8 million, up from CHF 14.3 million in June, and exceeded its cash flow breakeven point for the first time.

Kuros continues to invest in its Project Fusion and is expanding its market presence internationally, with new distributors in Australia and the UK, as well as commercial clearances in the UAE and Qatar.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Kuros Biosciences AG